Answer
The safety and efficacy of Lemtrada (alemtuzumab) in children with multiple sclerosis aged 0 to 18 years have not yet been established, and no data are available.
Sources for this answer
- LEMTRADA 12 mg concentrate for solution for infusionSANOFI · emc · SmPC §4.2 Posology and method of administration · Version 2Document updated
Sources checked